Actelion Pharmaceuticals Ltd.
http://www1.actelion.com/en/index.page
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Actelion Pharmaceuticals Ltd.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Boston Scientific Bets Big On Monitoring; Buys Preventice For Up To $1.25Bn
The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.
CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
GSK Ends Tough Week With Ulcerative Colitis Therapy Termination
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
Company Information
- Other Names / Subsidiaries
-
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc